Ebselen in Acute Ischemic Stroke

Stroke - Tập 29 Số 1 - Trang 12-17 - 1998
Takenori Yamaguchi1,2,3,4,5,6,7, Keiji Sano1,2,8,3,4,6,7, Kintomo Takakura1,2,9,3,4,6,7, Isamu Saito1,2,10,3,4,6,7, Yukito Shinohara1,2,3,4,6,7,11, Takao Asano1,2,3,4,12,6,7, Hajime Yasuhara1,2,13,3,4,6,7
1From the National Cardiovascular Center, Osaka (T.Y.); Fuji Brain Institute Hospital, Shizuoka (K.S.); Tokyo Women’s Medical College, Tokyo (K.T.); Kyorin University, School of Medicine, Tokyo (I.S.); Tokai University, School of Medicine, Kanagawa (Y.S.); Saitama Medical Center School, Saitama (T.A.); and Showa University, School of Medicine, Tokyo (H.Y.) (Japan).
2Fuji Brain Institute Hospital, Shizuoka (K.S.)
3Kyorin University, School of Medicine, Tokyo (I.S.)
4Saitama Medical Center School, Saitama (T.A.)
5Takenori Yamaguchi From the National Cardiovascular Center, Osaka (T.Y.)
6Tokai University, School of Medicine, Kanagawa (Y.S.)
7Tokyo Women's Medical College, Tokyo (K.T.)
8Keiji Sano From the National Cardiovascular Center, Osaka (T.Y.)
9Kintomo Takakura From the National Cardiovascular Center, Osaka (T.Y.)
10Isamu Saito From the National Cardiovascular Center, Osaka (T.Y.)
11Yukito Shinohara From the National Cardiovascular Center, Osaka (T.Y.)
12Takao Asano From the National Cardiovascular Center, Osaka (T.Y.)
13Hajime Yasuhara From the National Cardiovascular Center, Osaka (T.Y.)

Tóm tắt

Background and Purpose —The effect of ebselen, a seleno-organic compound with antioxidant activity through a glutathione peroxidase–like action, on the outcome of acute ischemic stroke was evaluated in a multicenter, placebo-controlled, double-blind clinical trial. Methods —Patients diagnosed as having acute ischemic stroke who could receive drug treatment within 48 hours of stroke onset were enrolled. Oral administration of ebselen granules suspended in water (150 mg BID) or placebo was started immediately after admission and was continued for 2 weeks. The major end points were the Glasgow Outcome Scale scores at 1 month and 3 months after the start of treatment. The modified Mathew Scale and modified Barthel Index scores at 1 month and 3 months were also studied as secondary outcome measures. Results —Three hundred two patients were enrolled in the trial. Intent-to-treat analysis of 300 patients (151 given ebselen and 149 given placebo) revealed that ebselen treatment achieved a significantly better outcome than placebo at 1 month ( P =.023, Wilcoxon rank sum test) but not at 3 months ( P =.056, Wilcoxon rank sum test). The improvement was significant in patients who started ebselen within 24 hours of stroke onset but not in those who started treatment after 24 hours. There was a corresponding improvement in the modified Mathew Scale and modified Barthel Index scores. Conclusions —Early treatment with ebselen improved the outcome of acute ischemic stroke. Ebselen may be a promising neuroprotective agent.

Từ khóa


Tài liệu tham khảo

10.1016/0006-2952(84)90083-2

10.1016/0006-2952(84)90084-4

10.1016/0006-2952(88)90591-6

10.1016/0006-2952(85)90493-9

10.1016/0006-2952(85)90569-6

10.3171/jns.1992.77.3.0337

10.1016/0891-5849(89)90057-9

Johshita H, Sasaki T, Matsui T, Hanamura T, Masayasu H, Asano T, Takakura K. Effects of ebselen (PZ51) on ischaemic brain oedema after focal ischaemia in cats. Acta Neurochir (Wien). 1990;51:239–241.

10.1016/0304-3940(94)11226-9

Matsui T Johshita H Asano T Tanaka J. Effect of a free radical scavenger ebselen on cerebral ischemia. In: Krieglstein J Oberpichler H eds. Pharmacology of Cerebral Ischemia. Stuttgart Germany: Wissenschaftliche Verlagsgesellschaft mbH; 1990:363–367.

10.1038/sj.bjp.0701426

10.1227/00006123-198001000-00001

10.1016/S0140-6736(74)91639-0

10.3171/jns.1986.64.3.0420

10.1016/S0140-6736(75)92830-5

10.1056/NEJM198801283180402

10.1161/str.20.6.2728043

10.1016/0304-3940(92)90933-X

10.1016/0006-2952(96)00109-8

10.1248/bpb1978.10.595

10.1016/0922-4106(94)90218-6

10.1021/tx950115u

10.1111/j.2042-7158.1996.tb05879.x

Thông tin
Thông tin xuất bản

Stroke

Tập 29 Số 1

12-17

Thông tin tác giả